{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:49:10Z","timestamp":1791571750362,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06602-9","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T07:49:59Z","timestamp":1759823399000},"page":"5223-5236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy"],"prefix":"10.1007","volume":"104","author":[{"given":"Concetta","family":"Conticello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Del Fabro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Mele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Mina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bringhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Orofino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Antonioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pulini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"De Paoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Za","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Cotzia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Casson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Prete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Citiso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Liberatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Margiotta-Casaluci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Mor\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Attucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Accardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velia","family":"Bongarzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Mangiacavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Mannina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Garibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Rizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Di Cecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardino","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Uccello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cirino","family":"Botta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Leotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Vincelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Piciocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Marsili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Patriarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Zambello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Boccadoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Offidani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Petrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"issue":"2","key":"6602_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/leu.2017.329","volume":"32","author":"CS Chim","year":"2018","unstructured":"Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC (2018) Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia 32(2):252\u2013262. https:\/\/doi.org\/10.1038\/leu.2017.329","journal-title":"Leukemia"},{"key":"6602_CR2","doi-asserted-by":"publisher","unstructured":"Kumar SK (2024) What is the ideal approach-doublet, triplet, or quadruplet(s)? Hematology Am Soc Hematol Educ Program. Dec 6;2024(1):551\u2013560. https:\/\/doi.org\/10.1182\/hematology.2024000581. PMID: 39644003; PMCID: PMC11665711","DOI":"10.1182\/hematology.2024000581"},{"issue":"8","key":"6602_CR3","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.3324\/haematol.2023.283058","volume":"109","author":"M Engelhardt","year":"2024","unstructured":"Engelhardt M, Kort\u00fcm KM, Goldschmidt H, Merz M (2024) Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible. Haematologica 109(8):2420\u20132435. https:\/\/doi.org\/10.3324\/haematol.2023.283058PMID: 38356448; PMCID: PMC11290544","journal-title":"Haematologica"},{"key":"6602_CR4","doi-asserted-by":"publisher","unstructured":"Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P (2017) Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 18(10):1327\u20131337. https:\/\/doi.org\/10.1016\/S1470-2045(17)30578-8","DOI":"10.1016\/S1470-2045(17)30578-8"},{"key":"6602_CR5","doi-asserted-by":"crossref","unstructured":"Keith Stewart SV, Rajkumar MA, Dimopoulos Tam\u00e1s, Masszi I, \u0160pi\u010dka A, Oriol R, H\u00e1jek L, Rosi\u00f1ol DS, Siegel, Georgi G, Mihaylov AJ, Jakubowiak, Jesus F, San-Miguel PD, Ludwig H, Wang M, Vladim\u00edr, Maisnar J, Minarik MD, William PD, Bensinger I (2015) Maria-Victoria Mateos, Dina Ben-Yehuda, Vishal Kukreti, Naseem Zojwalla, Margaret E. Tonda,Xinqun Yang, Biao Xing, Philippe Moreau, and Antonio Palumbo, for the ASPIRE InvestigatorsCarfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. N Engl J Med ;372:142\u2009\u2013\u200952","DOI":"10.1056\/NEJMoa1411321"},{"key":"6602_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-018-0583-7","volume":"11","author":"M Dimopoulos","year":"2018","unstructured":"Dimopoulos M, Wang M, Maisnar V, Minarik J, Bensinger W, Mateos MV, Obreja M, Blaedel J, Moreau P (2018) Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol 11:49","journal-title":"J Hematol Oncol"},{"key":"6602_CR7","doi-asserted-by":"crossref","unstructured":"Lisa B, Leypoldt D, Tichy B, Besemer M, H\u00e4nel MS, Raab C, Mann M, Munder HC, Reinhardt A, Nogai M, G\u00f6rner R, Peceny P, Staib A, Dieing H, Einsele A, Jauch M, Hundemer (2024) Manola Zago, Ema Po\u017eek, Axel Benner, Carsten Bokemeyer, Hartmut Goldschmidt, Katja C Weisel. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma. J Clin Oncol. ;42(1):26\u201337","DOI":"10.1200\/JCO.23.01696"},{"issue":"6","key":"6602_CR8","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1016\/S2352-3026(24)00070-X","volume":"11","author":"OD Elizabeth","year":"2024","unstructured":"Elizabeth OD, Mo C, Yee AJ, Nadeem O, Laubach J, Rosenblatt J, Munshi N, Midha S, Cirstea D, Chrysafi P, Horick N, Richardson PG (2024) Noopur raje. Isatuximab, carfilzomib, Lenalidomide and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single arm, phase-2 trial. Lancet Haematol 11(6):e415\u2013e424","journal-title":"Lancet Haematol"},{"key":"6602_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41408-024-01045-3","volume":"14","author":"A Benjamin","year":"2024","unstructured":"Benjamin A, Derman J, Cooperrider J, Rosenblatt DE, Avigan M, Rampurwala D, Barnidge A, Major T, Karrison K, Jiang A, Ramsland (2024) Tadeusz kubicki, Andrzej J jakubowiak. Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J 14:87","journal-title":"Blood Cancer J"},{"issue":"12","key":"6602_CR10","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"P Francesca Gay","year":"2021","unstructured":"Francesca Gay P, Musto DR-S, Bertamini L, Belotti A, Galli M, Offidani M, Zamagni E, Ledda A, Grasso M, Ballanti S, Spadano A (2021) Michele cea, Francesca patriarca, Mattia d\u2019agostino, Andrea capra, Nicola giuliani, Paolo de fabritiis, Sara aquino, Angelo palmas, Barbara gamberi, Renato zambello, Maria Teresa petrucci, Paolo corradini, Michele cavo, Mario boccadoro. Carfilzomib with cyclophosphamide and dexamethasone or Lenalidomide and dexamethasone plus autologous transplantation or Carfilzomib plus Lenalidomide and dexamethasone, followed by maintenance with Carfilzomib plus Lenalidomide or Lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol 22(12):1705\u20131720","journal-title":"Lancet Oncol"},{"key":"6602_CR11","doi-asserted-by":"crossref","unstructured":"Bonello F, Cetani G, Bertamini L, Gay F, Larocca A. Moving Toward Continuous Therapy in Multiple Myeloma. Clin Hematol Int. ;1(4):189\u2013200. doi:, Ntanasis-Stathopoulos I (2019) International Myeloma Society. Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting 2018.Clin Lymphoma Myeloma Leuk. 2019;19(7):e324-e336. doi: 10.1016\/j.clml.2019.03.008. Epub 2019 Apr 4.","DOI":"10.1016\/j.clml.2019.03.008"},{"key":"6602_CR12","doi-asserted-by":"publisher","first-page":"9710","DOI":"10.3390\/curroncol30110705","volume":"30","author":"M Fazio","year":"2023","unstructured":"Fazio M, Del Fabro V, Parrinello NL, Allegra A, Markovic U, Botta C, Accardi F, Vincelli ID, Leotta S, Elia F, Esposito B, Garibaldi B, Sapuppo G, Orofino A, Romano A, Palumbo GA, Di Raimondo F, Conticello C (2023) Multiple myeloma in 2023 ways: from trials to real life. Curr Oncol 30:9710\u20139733","journal-title":"Curr Oncol"},{"key":"6602_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8101695","volume":"8","author":"MS Parisi","year":"2019","unstructured":"Parisi MS, Leotta S, Romano A, Del Fabro V, Martino EA, Calafiore V, Giubbolini R, Markovic U, Leotta V, Di Giorgio MA, Tibullo D, Di Raimondo F, Conticello C (2019) Clinical benefit of long-term disease control with pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma patients. J Clin Med 8:1695","journal-title":"J Clin Med"},{"key":"6602_CR14","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/leu.2009.273","volume":"24","author":"H Avet-Loiseau","year":"2010","unstructured":"Avet-Loiseau H, Soulier J, Fermand J-P, Yakoub-Agha I, Attal M, Hulin C, Garderet L, Belhadj K, Dorvaux V, Minvielle S, Moreau P (2010) Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leukemia 24:623\u2013628","journal-title":"Leukemia"},{"key":"6602_CR15","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/leu.2010.175","volume":"24","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos MA, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M, Iakovaki M, Matsouka C, Mparmparoussi D, Roussou M, Efstathiou E, Terpos E (2010) Treatment of patients with relapsed\/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 24:1769\u20131778","journal-title":"Leukemia"},{"issue":"23","key":"6602_CR16","doi-asserted-by":"publisher","first-page":"6017","DOI":"10.3390\/cancers13236017","volume":"13","author":"U Markovic","year":"2021","unstructured":"Markovic U, Romano A, Bellofiore C, Condorelli A, Garibaldi B, Bulla A, Duminuco A, Del Fabro V, Di Raimondo F, Conticello C (2021) Role of serum free light chain assay in relapsed\/refractory multiple myeloma. A Real-Life unicentric retrospective study. Cancers (Basel) 13(23):6017. https:\/\/doi.org\/10.3390\/cancers13236017PMID: 34885127; PMCID: PMC8656731","journal-title":"Cancers (Basel)"},{"key":"6602_CR17","doi-asserted-by":"publisher","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blad\u00e9 J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. ;17(8):e328-e346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6. PMID: 27511158","DOI":"10.1016\/S1470-2045(16)30206-6"},{"issue":"33","key":"6602_CR18","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.1200\/JCO.2010.29.2201","volume":"28","author":"JD Rizzo","year":"2010","unstructured":"Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk D, Goode MJ, Jakubowski AA, Regan DH (2010) Somerfield. American society of clinical oncology\/american society of hematology clinical practice guideline update on the use of Epoetin and Darbepoetin in adult patients with cancer. J Clin Oncol 28(33):4996\u20135010","journal-title":"J Clin Oncol"},{"key":"6602_CR19","doi-asserted-by":"crossref","unstructured":"Aapro MS, Bohlius J, Cameron DA, Lago LD, Peter Donnelly J, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (January 2011) 2010 update of EORTC guidelines for the use of granulocytecolony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J CancerVolume 47(1):8\u201332","DOI":"10.1016\/j.ejca.2010.10.013"},{"key":"6602_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1157610","volume":"13","author":"A Duminuco","year":"2023","unstructured":"Duminuco A, Romano A, Leotta D, La Spina E, Cambria D, Bulla A, Del Fabro V, Tibullo D, Giallongo C, Palumbo GA, Conticello C, Di Raimondo F (2023) Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab\/cilgavimab. Front Oncol 13:1157610. https:\/\/doi.org\/10.3389\/fonc.2023.1157610","journal-title":"Front Oncol"},{"key":"6602_CR21","doi-asserted-by":"publisher","unstructured":"Bringhen S, Milan A, Ferri C, W\u00e4sch R, Gay F, Larocca A, Salvini M, Terpos E, Goldschmidt H, Cavo M, Petrucci MT, Ludwig H, Auner HW, Caers J, Gramatzki M, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M (2018) Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European myeloma network (EMN) and Italian society of arterial hypertension (SIIA).European hematology association, the European myeloma network and the Italian society of arterial hypertension.Haematologica. 103(9):1422\u20131432. https:\/\/doi.org\/10.3324\/haematol.2018.191288. Epub 2018 Jul 26.PMID: 30049825","DOI":"10.3324\/haematol.2018.191288"},{"key":"6602_CR22","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliot V, Fernandez M, O\u2019Neal L et al (2019) The REDCap consortium: Building an international community of software partners. J Biomed Inf 95:103208","journal-title":"J Biomed Inf"},{"key":"6602_CR23","doi-asserted-by":"publisher","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed). ;112(1):90\u201392. English, Spanish. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009. Epub 2020 Sep 3. PMID: 32891586","DOI":"10.1016\/j.ad.2019.05.009"},{"key":"6602_CR24","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3390\/jcm8060877","volume":"8","author":"A Concetta Conticello","year":"2019","unstructured":"Concetta Conticello A, Romano VD, Fabro EA, Martino V, Calafiore G, Sapienza V, Leotta (2019) Marina Silvia parisi, Uros markovic, Bruno garibaldi, Salvatore leotta, Emilia cotzia, Vanessa innao, Donato mannina, Santo neri, Maurizio musso, Renato scalone, Clotilde cangialosi, Francesco acquaviva, Giovanni cardinale, Anxur merenda, cinzia maugeri, Giuseppina uccello, Massimo poidomani, Giuseppe longo, melania carlisi, Daniele tibullo, Francesco Di raimondo. Feasibility, tolerability and efficacy of Carfilzomib in combination with Lenalidomide and dexamethasone in relapsed refractory myeloma patients: A retrospective Real-Life survey of the Sicilian myeloma network. J Clin Med 8:877","journal-title":"J Clin Med"},{"key":"6602_CR25","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1007\/s00277-020-04158-4","volume":"99","author":"S Palmieri","year":"2020","unstructured":"Palmieri S, Rocco S, Vitagliano O, Catalano L, Cerchione C, Vincelli ID, Scopelliti A, Gentile M, Farina G, Barone M, Gagliardi A, Esposito D, Arcamone M, Amico V, Fontana R, Sementa A, Sica A, Svanera G, Pane F, Ferrara F (2020) KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients. Ann Hematol 99:2903\u20132909","journal-title":"Ann Hematol"},{"key":"6602_CR26","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00277-020-04329-3","volume":"100","author":"A Mele","year":"2021","unstructured":"Mele A, Prete E, De Risi C, Citiso S, Greco G, Falcone AP, Sanpaolo G, Mele G, Giannotta A, Vergine C, Reddiconto G, Palazzo G, Sabatelli S, Germano C, Miccolis R, Curci P, Palumbo G, Offidani M, Rizzi R, Cascavilla N, Pastore D, Di Renzo N, Mazza P, Tarantini G, Guarini A, Capalbo S, Specchia G, Greco A, De Francesco R, Sibilla S, Tonialini L, Morciano MR, Pavone V (2021) Carfilzomib, lenalidomide, and dexamethasone in relapsed\/refractory multiple myeloma patients: the real-life experience of rete ematologica Pugliese (REP). Ann Hematol 100:429\u2013436","journal-title":"Ann Hematol"},{"key":"6602_CR27","doi-asserted-by":"crossref","unstructured":"Serena Rocchi P, Tacchetti L, Pantani K, Mancuso I, Rizzello M, Scalese L, Dozza G, Marzocchi M, Martello G, Baril\u00e0 E, Antonioli M, Staderini G, Buda (2021) Mario Petrini, Michele Cea, Micol Quaresima, Anna Furlan, Angela Bonalumi, Michele Cavo, Elena Zamagni. A real-world efficacy and safety analysis of combinedcarfilzomib, lenalidomide, and dexamethasone (KRd) inrelapsed\/refractory multiple myeloma. Hematological Oncology. ;39:41\u201350","DOI":"10.1002\/hon.2820"},{"key":"6602_CR28","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/hon.3035","volume":"40","author":"EA Martino","year":"2022","unstructured":"Martino EA, Conticello C, Zamagni E, Pavone V, Palmieri S, Musso M, Tacchetti P, Mele A, Catalano L, Vigna E, Bruzzese A, Mendicino F, Botta C, Vincelli ID, Farina G, Barone M, Cangialosi C, Mancuso K, Rizziello I, Rocchi S, Falcone AP, Mele G, Reddiconto G, Garibaldi B, Iaccino E, Tripepi G, Gamberi B, Di Raimondo F, Musto P, Neri A, Cavo M, Morabito F, Gentile M (2022) Carfilzomib combined with lenalidomide and dexamethasone(KRd) as salvage therapy for multiple myeloma patients: Italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials. Hematol Oncol 40:1009\u20131019","journal-title":"Hematol Oncol"},{"key":"6602_CR29","doi-asserted-by":"publisher","first-page":"1162990","DOI":"10.3389\/fonc.2023.1162990","volume":"13","author":"E Antonioli","year":"2023","unstructured":"Antonioli E, Pilerci S, Attucci I, Buda G, Gozzetti A, Candi V, Simonetti F, Giudice MLD, Ciofini S, Staderini M, Grammatico S, Buzzichelli A, Messeri M, Bocchia M, Galimberti S, Vannucchi AM (2023) Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the regional Tuscan myeloma network. FrontOncol 13:1162990. https:\/\/doi.org\/10.3389\/fonc.2023.1162990PMID: 37182182; PMCID: PMC10166989","journal-title":"FrontOncol"},{"key":"6602_CR30","doi-asserted-by":"publisher","unstructured":"Lee JH, Choi J, Min CK, Park SS, Jo JC, Lee YJ, Kim JS, Eom HS, Jung J, Moon JH, Cho HJ, Lee MW, Yoon SS, Byun JM, Lee JH, Lee JJ, Jung SH, Shin HJ, Kim DY, Yi JH, Lee SS, Do YR, Yoon DH, Cho H, Lee WS, Lee HS, Uhm J, Kim HJ, Jang HR, Kim SH, Kim K (2024) Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 study.haematologica. 109(11):3681\u20133692. https:\/\/doi.org\/10.3324\/haematol.2024.285534. PMID: 38841794; PMCID: PMC11532698","DOI":"10.3324\/haematol.2024.285534"},{"issue":"9","key":"6602_CR31","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1159\/000509018","volume":"43","author":"HT Steinmetz","year":"2020","unstructured":"Steinmetz HT, Singh M, Lebioda A, Gonzalez-McQuire S, Rieth A, Schoehl M, Poenisch W (2020) Patient characteristics and outcomes of relapsed\/refractory multiple myeloma in patients treated with proteasome inhibitors in Germany. Oncol Res Treat 43(9):449\u2013459 Epub 2020 Jul 21. PMID: 32694243; PMCID: PMC7845445","journal-title":"Oncol Res Treat"},{"issue":"1","key":"6602_CR32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jha2.828","volume":"5","author":"K Laribi","year":"2023","unstructured":"Laribi K, Leleu X, Texier N, Germain R, Touzeau C, Hammoud M, Payssot A, Schulmann S, Le Calloch R, Trebouet A, Chaoui D, David S, Benbrahim O, Benramdane R, Charvet-Rumpler A, Jadeau C, Rouanet E, Decaux O, Perrot A (2023) Real-life effectiveness of Carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: the CARMYN study. EJHaem 5(1):55\u201360. https:\/\/doi.org\/10.1002\/jha2.828PMID: 38406520; PMCID: PMC10887228","journal-title":"EJHaem"},{"key":"6602_CR33","doi-asserted-by":"publisher","unstructured":"Garcia-Gui\u00f1on A, Charry PA, Jimenez M, Sarra J, Delgado I, Segura de la Torre L, Santaliestra M, Garcia-Pintos M, Gonzalez Y, Senin A, Motll\u00f3 C, Abella E, Cabezudo E, Granell M, Sancho E, Herranz MJ, Seres Y, Gironella M, Soler JA, Marti-Tutusaus JM, Ben Azaiz R Fernandez de Larrea C. Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed \/ refractory multiple myeloma. Ann Hematol. 2025 Feb 15. https:\/\/doi.org\/10.1007\/s00277-025-06240-1. Epub ahead of print. PMID: 39954075","DOI":"10.1007\/s00277-025-06240-1"},{"key":"6602_CR34","doi-asserted-by":"crossref","unstructured":"Deevyashali S, Parekh YKR, Tiger KT, Jamouss (2024) Justin Hassani, Maroun Bou Zerdan, Shahzad Raza. Updates on Therapeutic Strategies in the Treatment of Relapsed\/Refractory Multiple Myeloma.Cancers 16, 2931","DOI":"10.3390\/cancers16172931"},{"issue":"19","key":"6602_CR35","doi-asserted-by":"publisher","first-page":"5012","DOI":"10.1182\/bloodadvances.2024013101","volume":"8","author":"A Meletios","year":"2024","unstructured":"Meletios A, Dimopoulos D, Coriu S, Delimpasi I, Spi\u02c7cka T, Upchurch B, Fang R, Talpur E, Faber M, Beksac, Leleu X (2024) A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed\/refractory multiple myeloma. Blood Adv 8(19):5012\u20135021. https:\/\/doi.org\/10.1182\/bloodadvances.2024013101(?)","journal-title":"Blood Adv"}],"updated-by":[{"DOI":"10.1007\/s00277-025-06713-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000}},{"DOI":"10.1007\/s00277-026-06880-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000}}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06602-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06602-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06602-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T01:11:08Z","timestamp":1770858668000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06602-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6602"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06602-9","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00277-026-06880-x","URL":"https:\/\/doi.org\/10.1007\/s00277-026-06880-x","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00277-025-06713-3","URL":"https:\/\/doi.org\/10.1007\/s00277-025-06713-3","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved bythe independent ethics committee of the coordinating center (n.34\/2019\/PO). All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2024.Informed consent for data processing was obtained from all patients. Carfilzomib-lenalidomide based treatments were performed according to current clinical practice at local institutions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}